Ardisiacrispin B is primarily studied for its potential anticancer properties. It has shown cytotoxic effects against various cancer cell lines, making it a subject of interest in oncology research. The compound exhibits the ability to induce apoptosis, or programmed cell death, in tumor cells, particularly in liver and breast cancer models. Its mechanism involves disrupting mitochondrial function and increasing reactive oxygen species within cancer cells, leading to cell cycle arrest.

In addition to its anticancer activity, Ardisiacrispin B demonstrates anti-inflammatory and antimicrobial effects. It may modulate key inflammatory pathways, suggesting possible use in treating chronic inflammatory conditions. Research also indicates inhibitory activity against certain bacteria and fungi, highlighting its potential as a lead compound in developing new antimicrobial agents.

Due to its natural origin and bioactivity, Ardisiacrispin B is being explored for use in pharmaceuticals, especially in targeted therapies where natural products with selective toxicity are valuable. However, most studies remain in the preclinical stage, and further research is needed to evaluate its efficacy and safety in humans.